X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.
Lead Product(s): Ent001
Therapeutic Area: Gastroenterology Product Name: Ent001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.
Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roche Venture Fund
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 28, 2021
Details:
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.
Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $33.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
